vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and MATTHEWS INTERNATIONAL CORP (MATW). Click either name above to swap in a different company.

BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($406.6M vs $284.8M, roughly 1.4× MATTHEWS INTERNATIONAL CORP). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 15.3%, a 45.1% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs -29.1%). BIOCRYST PHARMACEUTICALS INC produced more free cash flow last quarter ($291.2M vs $-57.2M).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Matthews Aurora Funeral Solutions is one of the largest manufacturers of caskets and funerary urns in the United States, selling over 38% of the country's caskets as of 2005. The Aurora, Indiana–based company is a subsidiary of Pittsburgh-based Matthews International. The company makes both wooden and metal caskets and urns for holding cremated remains. It also provides supplies and consulting services for funeral homes.

BCRX vs MATW — Head-to-Head

Bigger by revenue
BCRX
BCRX
1.4× larger
BCRX
$406.6M
$284.8M
MATW
Growing faster (revenue YoY)
BCRX
BCRX
+238.2% gap
BCRX
209.1%
-29.1%
MATW
Higher net margin
BCRX
BCRX
45.1% more per $
BCRX
60.5%
15.3%
MATW
More free cash flow
BCRX
BCRX
$348.4M more FCF
BCRX
$291.2M
$-57.2M
MATW

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BCRX
BCRX
MATW
MATW
Revenue
$406.6M
$284.8M
Net Profit
$245.8M
$43.6M
Gross Margin
97.7%
35.0%
Operating Margin
64.0%
34.2%
Net Margin
60.5%
15.3%
Revenue YoY
209.1%
-29.1%
Net Profit YoY
1017.5%
1356.6%
EPS (diluted)
$1.13
$1.39

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
MATW
MATW
Q4 25
$406.6M
$284.8M
Q3 25
$159.4M
Q2 25
$163.4M
Q1 25
$145.5M
Q4 24
$131.5M
Q3 24
$117.1M
Q2 24
$109.3M
Q1 24
$92.8M
Net Profit
BCRX
BCRX
MATW
MATW
Q4 25
$245.8M
$43.6M
Q3 25
$12.9M
Q2 25
$5.1M
Q1 25
$32.0K
Q4 24
$-26.8M
Q3 24
$-14.0M
Q2 24
$-12.7M
Q1 24
$-35.4M
Gross Margin
BCRX
BCRX
MATW
MATW
Q4 25
97.7%
35.0%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Q1 24
98.6%
Operating Margin
BCRX
BCRX
MATW
MATW
Q4 25
64.0%
34.2%
Q3 25
18.6%
Q2 25
18.2%
Q1 25
14.6%
Q4 24
-3.4%
Q3 24
6.6%
Q2 24
8.0%
Q1 24
-15.6%
Net Margin
BCRX
BCRX
MATW
MATW
Q4 25
60.5%
15.3%
Q3 25
8.1%
Q2 25
3.1%
Q1 25
0.0%
Q4 24
-20.4%
Q3 24
-12.0%
Q2 24
-11.6%
Q1 24
-38.1%
EPS (diluted)
BCRX
BCRX
MATW
MATW
Q4 25
$1.13
$1.39
Q3 25
$0.06
Q2 25
$0.02
Q1 25
$0.00
Q4 24
$-0.13
Q3 24
$-0.07
Q2 24
$-0.06
Q1 24
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
MATW
MATW
Cash + ST InvestmentsLiquidity on hand
$274.7M
$31.4M
Total DebtLower is stronger
$529.8M
Stockholders' EquityBook value
$-119.2M
$543.2M
Total Assets
$514.2M
$1.6B
Debt / EquityLower = less leverage
0.98×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
MATW
MATW
Q4 25
$274.7M
$31.4M
Q3 25
$212.9M
Q2 25
$260.0M
Q1 25
$295.1M
Q4 24
$320.9M
Q3 24
$96.8M
Q2 24
$78.4M
Q1 24
$84.3M
Total Debt
BCRX
BCRX
MATW
MATW
Q4 25
$529.8M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BCRX
BCRX
MATW
MATW
Q4 25
$-119.2M
$543.2M
Q3 25
$-387.9M
Q2 25
$-421.6M
Q1 25
$-451.9M
Q4 24
$-475.9M
Q3 24
$-468.6M
Q2 24
$-475.6M
Q1 24
$-476.2M
Total Assets
BCRX
BCRX
MATW
MATW
Q4 25
$514.2M
$1.6B
Q3 25
$446.4M
Q2 25
$457.2M
Q1 25
$480.0M
Q4 24
$490.4M
Q3 24
$491.3M
Q2 24
$472.4M
Q1 24
$467.9M
Debt / Equity
BCRX
BCRX
MATW
MATW
Q4 25
0.98×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
MATW
MATW
Operating Cash FlowLast quarter
$292.0M
$-52.0M
Free Cash FlowOCF − Capex
$291.2M
$-57.2M
FCF MarginFCF / Revenue
71.6%
-20.1%
Capex IntensityCapex / Revenue
0.2%
1.8%
Cash ConversionOCF / Net Profit
1.19×
-1.19×
TTM Free Cash FlowTrailing 4 quarters
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
MATW
MATW
Q4 25
$292.0M
$-52.0M
Q3 25
$41.6M
Q2 25
$41.3M
Q1 25
$-27.5M
Q4 24
$-5.2M
Q3 24
$8.2M
Q2 24
$-1.4M
Q1 24
$-53.7M
Free Cash Flow
BCRX
BCRX
MATW
MATW
Q4 25
$291.2M
$-57.2M
Q3 25
$40.3M
Q2 25
$41.1M
Q1 25
$-27.7M
Q4 24
$-5.9M
Q3 24
$8.2M
Q2 24
$-1.5M
Q1 24
$-53.9M
FCF Margin
BCRX
BCRX
MATW
MATW
Q4 25
71.6%
-20.1%
Q3 25
25.3%
Q2 25
25.2%
Q1 25
-19.0%
Q4 24
-4.5%
Q3 24
7.0%
Q2 24
-1.4%
Q1 24
-58.1%
Capex Intensity
BCRX
BCRX
MATW
MATW
Q4 25
0.2%
1.8%
Q3 25
0.8%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.3%
Cash Conversion
BCRX
BCRX
MATW
MATW
Q4 25
1.19×
-1.19×
Q3 25
3.23×
Q2 25
8.12×
Q1 25
-859.91×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons